We are live on ! Find out more
REGN icon

Regeneron Pharmaceuticals
REGN

1,331 hedge funds and large institutions have $98.9B invested in Regeneron Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 125 funds opening new positions, 545 increasing their positions, 428 reducing their positions, and 84 closing their positions.

New
Increased
Maintained
Reduced
Closed

49% more first-time investments, than exits

New positions opened: 125 | Existing positions closed: 84

27% more repeat investments, than reductions

Existing positions increased: 545 | Existing positions reduced: 428

16% more funds holding in top 10

Funds holding in top 10: 25 → 29 (+4)

11% more capital invested

Capital invested by funds: $89.2B → $98.9B (+$9.73B)

2% more funds holding

Funds holding: 1,309 → 1,331 (+22)

0.59% more ownership

Funds ownership: 86.29% → 86.89% (+0.59%)

30% less call options, than puts

Call options by funds: $1.09B | Put options by funds: $1.55B

Holders
1,331
Holders Change
+22
Holders Change %
+1.68%
% of All Funds
19.22%
Holding in Top 10
29
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+16%
% of All Funds
0.42%
New
125
Increased
545
Reduced
428
Closed
84
Calls
$1.09B
Puts
$1.55B
Net Calls
-$465M
Net Calls Change
+$195M

Top Buyers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
+$533M
2
Goldman Sachs
Goldman Sachs
New York
+$298M
3
Franklin Resources
Franklin Resources
California
+$222M
4
Capital Research Global Investors
Capital Research Global Investors
California
+$160M
5
UBS AM
UBS AM
Illinois
+$158M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$140M
2
Marshall Wace
Marshall Wace
United Kingdom
-$137M
3
BlackRock
BlackRock
New York
-$119M
4
Pictet Asset Management
Pictet Asset Management
Switzerland
-$107M
5
Caisse de Depot et Placement du Quebec (CDPQ)
Caisse de Depot et Placement du Quebec (CDPQ)
Quebec, Canada
-$86.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
RFG
1301
RFP Financial Group
Georgia
$5.25K – – –
SA
1302
Scarborough Advisors
Maryland
$5.25K – – –
SC
1303
SouthState Corp
Florida
$5.25K +$3.88K +4 +400%
KA
1304
Kozak & Associates
Colorado
$5.12K – – –
HFM
1305
Hartford Financial Management
Connecticut
$4.21K – – –
CB
1306
CNB Bank
Pennsylvania
$4.2K – – –
FRA
1307
Front Row Advisors
California
$4.2K – – –
RWPA
1308
Richard W. Paul & Associates
Michigan
$4.2K – – –
ECM
1309
Everence Capital Management
Indiana
$3.33K – – –
CPG
1310
Cornerstone Planning Group
New Jersey
$3.21K +$1.94K +2 +200%
TWD
1311
True Wealth Design
Ohio
$3.15K +$969 +1 +50%
PPC
1312
Park Place Capital
Alabama
$3.15K -$3.88K -4 -57%
IHWM
1313
Iron Horse Wealth Management
Iowa
$3.15K – – –
LIM
1314
Longfellow Investment Management
Massachusetts
$3.15K +$969 +1 +50%
RFS
1315
Richardson Financial Services
Massachusetts
$3.15K +$1.94K +2 +200%
PI
1316
PEAK6 Investments
Illinois
$2.19K – – –
CTWM
1317
Cherry Tree Wealth Management
Minnesota
$2.1K – – –
MIM
1318
Macroview Investment Management
Maryland
$2.1K – – –
WWM
1319
Wolff Wiese Magana
California
$2.1K +$969 +1 +100%
BONH
1320
Bank of New Hampshire
New Hampshire
$2.1K – – –
CIAS
1321
CBIZ Investment Advisory Services
Ohio
$2.1K – – –
HWP
1322
Highline Wealth Partners
California
$2.1K – – –
CAM
1323
Creekmur Asset Management
Illinois
$2.1K +$969 +1 +100%
PO
1324
Private Ocean
California
$2.1K +$1.94K +2 New
RWM
1325
Ruedi Wealth Management
Illinois
$2.1K +$1.94K +2 New
51 52
53
54 55

REGN Hedge Fund Activity: Q2 2024 in Review

1,331 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q2 2024, worth a combined $98.9B — up 11% from $89.2B a quarter earlier.

Buyers outnumbered sellers: 125 funds opened new REGN positions and 84 closed out — a net gain of 41 holders — while 545 added to existing stakes and 428 trimmed.

The largest buyer was JP Morgan Chase, adding an estimated $533M. The largest seller was Fidelity Investments, cutting an estimated $140M.

  • 1,331 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q2 2024, up from 1,309 in Q1 2024.
  • Funds reported $98.9B of Regeneron Pharmaceuticals stock for Q2 2024, up 11% quarter-over-quarter.
  • 125 funds opened new Regeneron Pharmaceuticals positions in Q2 2024 and 84 closed out, a net change of +41 holders.
  • The largest Regeneron Pharmaceuticals buyer in Q2 2024 was JP Morgan Chase, an estimated $533M added.
  • The largest Regeneron Pharmaceuticals seller in Q2 2024 was Fidelity Investments, an estimated $140M sold.

Based on aggregated 13F filings for Q2 2024.